The global live cell encapsulation market is expected to record a CAGR of 3.97% from 2023 to 2033. In 2023, the market size is projected to reach a valuation of USD 219.06 million. By 2033, the valuation is likely to be worth USD 323.33 million.
Target-specific therapies and increased awareness of their potential benefits are the key reason for market growth. As a result, there has been a surge in investments from both public and private partnerships to support this technology.
Following are the Market’s Growth Drivers:
Increasing Demand for Regenerative Medicine:
Regenerative medicine is an emerging field that aims to restore the normal function of damaged or diseased tissues and organs. Live cell encapsulation plays a crucial role in regenerative medicine. As it enables the delivery of live cells to targeted sites, where they can regenerate damaged tissues. The increasing growth of the regenerative medicine market is driving the demand for live cell encapsulation technology.
Growing Investments in Research and Development:
Governments and private organizations are investing heavily in research and development activities. The aim behind the investment is to improve the efficacy and safety of live cell encapsulation. These investments are expected to fuel the growth of the market in the coming years.
Technological Advancements:
The development of new technologies has enabled the production of more efficient and effective live cell encapsulation systems. For instance, the use of microfluidics and 3D printing has improved the precision and scalability of live cell encapsulation, making it more commercially viable.
Rising Prevalence of Chronic Diseases:
Chronic diseases such as diabetes, Parkinson's disease, and cancer are on the rise globally. Live cell encapsulation has emerged as a promising therapy for these conditions. As it can deliver live cells to targeted sites and promote tissue regeneration. The increasing prevalence of chronic diseases is expected to drive the demand for live cell encapsulation in the coming years.
Increasing Awareness about the Benefits of Live Cell Encapsulation:
As more research is conducted on live cell therapy and its potential applications, healthcare providers and patients are increasingly aware of its benefits.
| Attributes | Value |
|---|---|
| Live Cell Encapsulation Value (2022) | USD 210.7 million |
| Live Cell Encapsulation Market Expected Value (2023) | USD 219.06 million |
| Live Cell Encapsulation Market Forecast Value (2033) | USD 323.33 million |
| Live Cell Encapsulation Market Expected CAGR (2023 to 2033) | 3.97% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Sernova Corp. Acquired Cell Pouch System:
In 2020, Sernova Corp., a clinical-stage company acquired the Cell Pouch System from a private firm, Sanwa Kagaku Kenkyusho Co. Ltd. This acquisition has enabled Sernova Corp. to expand its regenerative medicine product pipeline by integrating the Cell Pouch System, which is a live-cell encapsulation device.
Living Cell Technologies Limited Merged with Viacyte:
In 2019, Living Cell Technologies Limited, a biotechnology company that develops encapsulated cell therapies, merged with Viacyte. The company is focused on developing regenerative therapies for diabetes. This merger enabled the combined entity to expand its product portfolio and accelerate the development of encapsulated cell therapies for diabetes.
Evotec SE acquired Just Biotherapeutics:
In 2019, Evotec SE, a German drug discovery and development company, acquired Just Biotherapeutics. A company specializing in the development of engineered proteins for therapeutic use. This acquisition enabled Evotec SE to integrate Just Biotherapeutics' technology. This includes its live-cell encapsulation platform in its product portfolio and enhances its capabilities in the field of regenerative medicine.
These mergers and acquisitions have allowed companies to expand their product portfolios. Moreover, it leverages complementary technologies and strengthens its position in the live cell encapsulation market.
Overall, these factors may restrain the growth of the live cell encapsulation market. On that account, companies operating in this market might need to address these challenges to succeed.
Principal Consultant
The microencapsulation segment accounted for a significant market share of 64.17% in 2023. This technique involves the formulation of a bioactive substance into a particle size of 1 to 1000 μm in diameter.
Microencapsulation has several applications in therapeutic delivery for the treatment of various diseases, such as cancer, tuberculosis, diabetes, rheumatoid arthritis, and respiratory tract infection. For example, microencapsulated islets of Langerhans can be implanted in the body for long-term treatment of diabetes or other diseases that require organ transplantation.
The growth of the microencapsulation segment is primarily driven by its therapeutic applications. On the other hand, the nanoencapsulation segment is projected to expand at a significant CAGR during the forecast period.
Nanoencapsulation technology is widely used in the development of drug delivery systems. The delivery of encapsulated diagnostic/therapeutic agents depends on the size of the nanoparticle. Therefore, the use of nanoencapsulation technology is considered crucial in designing effective drug delivery systems, which is expected to drive segment growth.
In 2023, the drug delivery segment is expected to account for a significant revenue share of 44.60%.
The use of live cell encapsulation technology in the manufacturing of capsules, tablets, and parenteral dosage forms is crucial for effective drug delivery. Controlled drug delivery has enormous potential in diseases with progressive deterioration.
Live cell encapsulation provides advantages such as enhanced therapeutic effects, reduced drug dosage, lowered cytotoxicity, improved patient convenience, and compliance, which are driving the growth of this segment. Besides, the regenerative medicine segment is anticipated to record a rapid CAGR over the forecast period.
Regenerative medicine is an emerging field that uses stem cells as a cell-based therapy to regenerate or restore damaged tissues or organs. Stem cell encapsulation can provide various advantages in regenerative medicine, including improved cell viability, proliferation, and differentiation.
To support regenerative medicine, many industry players are implementing various strategies. For example, Invetech plans to deliver three GMP encapsulation devices in 2023 to support TreeFrog's in-house and partnered cell therapy programs in regenerative medicine and immuno-oncology. These types of initiatives are expected to drive the growth of the regenerative medicine segment during the forecast period.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
North America is expected to dominate the live cell encapsulation market, holding a market share of 36.72% in 2023. The region's significant market share can be attributed to several factors including:
North America's focus on research in the area of drug discovery is also contributing to the growth of the industry. The region is home to many innovators and key operating players, resulting in higher penetration of live cell encapsulation products and therapies. For example, ViaCyte, Inc. recently announced the initiation of phase 2 clinical study of encapsulated cell therapy. The clinical study is initiated to treat type 1 diabetes patients, highlighting the region's focus on innovation and advancing the field.
A Rise in Chronic Diseases:
The high incidence of chronic diseases, such as diabetes, cancer, and cardiovascular diseases in North America. This is creating a strong demand for regenerative medicine and cell-based therapies, including live cell encapsulation. This trend is expected to fuel significant growth in the live cell encapsulation market in the region. As healthcare providers seek innovative solutions to address the increasing burden of chronic diseases.
Favorable Regulatory Environment:
North America has a favorable regulatory environment for regenerative medicine and cell-based therapies. This has encouraged the development and commercialization of live cell encapsulation products and therapies. The streamlined regulatory pathway is expected to drive the growth of the market in North America.
Increasing Awareness about Personalized Medicine:
The concept of personalized medicine is gaining traction in Europe, which is driving the demand for cell-based therapies. Live cell encapsulation allows for the customization of therapy based on the patient’s individual needs.
Growing Demand for Organ Transplantation:
The shortage of organs for transplantation is a crucial challenge in Europe. Live cell encapsulation offers a potential solution to this problem, as it enables the production of artificial organs and tissues.
Asia Pacific: The Live Cell Encapsulation Market
The live cell encapsulation market in Asia Pacific is expected to record a significant CAGR over the forecast period. This growth can be attributed to the advancements in the biotechnology and pharmaceutical industries in emerging economies, particularly in India and China. The continuous government support for developing the pharmaceutical sector in these countries is also contributing to the region's profitable expansion.
The aging population in the Asia Pacific region is increasing rapidly, which is driving the demand for healthcare services. Live cell encapsulation is an effective approach for the treatment of age-related diseases such as Parkinson’s and Alzheimer’s disease. This in turn is driving the demand for this technology in the region.
Governments in the Asia Pacific region are providing support for the development of the biotechnology sector, which includes live cell encapsulation. This is creating opportunities for companies in the region to develop and commercialize new products and technologies in this field.
The global live cell encapsulation market is witnessing rapid growth, thanks to the strategic initiatives being implemented by key players in the industry. BIO INX, a manufacturing company recently launched innovative and biocompatible high-resolution bioink HYDROBIO INX for live cell encapsulation. Notable companies operating in this market include:
| Attribute | Details |
|---|---|
| Forecast Period | 2023 to 2033 |
| Historical Data Available for | 2018 to 2022 |
| Market Analysis | USD million for Value |
| Key Regions Covered | Polymer Type; Application; Method; RegionNorth America; Latin America; Europe; East Asia; South Asia & Pacific; The Middle East & Africa (MEA) |
| Key Countries Covered | United States, Canada, Brazil, Mexico, Germany, United Kingdom, France, Spain, Italy, China, Japan, South Korea, India, Indonesia, Malaysia, Singapore, Australia, New Zealand, Türkiye, South Africa, GCC Countries |
| Key Market Segments Covered | Polymer Type, Application, Method, Region |
| Key Companies Profiled | AUSTRIANOVA; Merck KGaA; Sphere Fluidics Ltd.; ViaCyte, Inc.; Blacktrace Holdings Ltd. (Dolomite Microfluidics); BIO INX; Living Cell Technologies Ltd.; Sigilon Therapeutics, Inc.; Isogen; Diatranz Otsuka Ltd. |
| Pricing | Available upon Request |
Drug delivery holds high revenue potential.
The United States, Canada, and China is estimated to dominate the global market.
The market is forecast to register a CAGR of 3.97% through 2033.
During 2018 to 2022, the market registered a CAGR of 3.97%.
Rising frequent chronic diseases are the current market trends.
1. Executive Summary 2. Market Overview 3. Market Background 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Polymer Type 5.1. Natural Polymers 5.2. Synthetic Polymers 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Method 6.1. Microencapsulation 6.2. Macroencapsulation 6.3. Nanoencapsulation 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Application 7.1. Drug Delivery 7.2. Regenerative Medicine 7.3. Cell Transplantation 7.4. Other Applications 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 8.1. North America 8.2. Latin America 8.3. Europe 8.4. South Asia 8.5. East Asia 8.6. Oceania 8.7. MEA 9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 15. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 16. Key Countries Market Analysis 17. Market Structure Analysis 18. Competition Analysis 18.1. AUSTRIANOVA 18.2. Merck KGaA 18.3. Sphere Fluidics Ltd. 18.4. ViaCyte, Inc. 18.5. Blacktrace Holdings Ltd. 18.6. BIO INX 18.7. Living Cell Technologies Ltd. 18.8. Sigilon Therapeutics, Inc. 18.9. Isogen 18.10. Diatranz Otsuka Ltd. 19. Assumptions & Acronyms Used 20. Research Methodology
Explore Healthcare Insights
View Reports
Live Cell Encapsulation Market
